Calreticulin exposure dictates the immunogenicity of cancer cell death - PubMed (original) (raw)
doi: 10.1038/nm1523. Epub 2006 Dec 24.
Antoine Tesniere, François Ghiringhelli, Gian Maria Fimia, Lionel Apetoh, Jean-Luc Perfettini, Maria Castedo, Grégoire Mignot, Theoharis Panaretakis, Noelia Casares, Didier Métivier, Nathanael Larochette, Peter van Endert, Fabiola Ciccosanti, Mauro Piacentini, Laurence Zitvogel, Guido Kroemer
Affiliations
- PMID: 17187072
- DOI: 10.1038/nm1523
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al. Nat Med. 2007 Jan.
Abstract
Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and mitomycin C do not induce immunogenic cell death. Here we show that anthracyclins induce the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knockdown of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase 1/GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase 1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anticancer immune responses and delineate a possible strategy for immunogenic chemotherapy.
Comment in
- A 'good death' for tumor immunology.
Storkus WJ, Falo LD Jr. Storkus WJ, et al. Nat Med. 2007 Jan;13(1):28-30. doi: 10.1038/nm0107-28. Nat Med. 2007. PMID: 17206130 No abstract available. - Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.
Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Ciampricotti M, et al. Nat Med. 2012 Mar 6;18(3):344-6; author reply 346. doi: 10.1038/nm.2652. Nat Med. 2012. PMID: 22395693 No abstract available.
Similar articles
- Calreticulin exposure increases cancer immunogenicity.
Clarke C, Smyth MJ. Clarke C, et al. Nat Biotechnol. 2007 Feb;25(2):192-3. doi: 10.1038/nbt0207-192. Nat Biotechnol. 2007. PMID: 17287754 No abstract available. - A 'good death' for tumor immunology.
Storkus WJ, Falo LD Jr. Storkus WJ, et al. Nat Med. 2007 Jan;13(1):28-30. doi: 10.1038/nm0107-28. Nat Med. 2007. PMID: 17206130 No abstract available. - Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.
Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G. Chaput N, et al. J Mol Med (Berl). 2007 Oct;85(10):1069-76. doi: 10.1007/s00109-007-0214-1. Epub 2007 May 22. J Mol Med (Berl). 2007. PMID: 17891368 Review. - Ecto-calreticulin in immunogenic chemotherapy.
Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G. Obeid M, et al. Immunol Rev. 2007 Dec;220:22-34. doi: 10.1111/j.1600-065X.2007.00567.x. Immunol Rev. 2007. PMID: 17979837 Review.
Cited by
- Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy.
Huang Z, Huang S, Song S, Ding Y, Zhou H, Zhang S, Weng L, Zhang Y, Hu Y, Yuan A, Dai Y, Luo Z, Wang L. Huang Z, et al. Nat Commun. 2024 Oct 8;15(1):8692. doi: 10.1038/s41467-024-53084-w. Nat Commun. 2024. PMID: 39375342 Free PMC article. - Prognosis of colorectal cancer, prognostic index of immunogenic cell death associated genes in response to immunotherapy, and potential therapeutic effects of ferroptosis inducers.
Lei M, Xiao M, Long Z, Lin T, Ding R, Quan Q. Lei M, et al. Front Immunol. 2024 Sep 20;15:1458270. doi: 10.3389/fimmu.2024.1458270. eCollection 2024. Front Immunol. 2024. PMID: 39372411 Free PMC article. - Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses.
Dong Y, Zhang Z, Luan S, Zheng M, Wang Z, Chen Y, Chen X, Tong A, Yang H. Dong Y, et al. J Immunother Cancer. 2024 Oct 2;12(10):e009710. doi: 10.1136/jitc-2024-009710. J Immunother Cancer. 2024. PMID: 39357981 Free PMC article. - Immunological effects of radiopharmaceutical therapy.
Shea AG, Idrissou MB, Torres AI, Chen T, Hernandez R, Morris ZS, Sodji QH. Shea AG, et al. Front Nucl Med. 2024 Apr 4;4:1331364. doi: 10.3389/fnume.2024.1331364. eCollection 2024. Front Nucl Med. 2024. PMID: 39355211 Free PMC article. Review. - Immune-modulative nano-gel-nano system for patient-favorable cancer therapy.
Kim SH, Han RT, Han HS, Kim YM. Kim SH, et al. Bioact Mater. 2024 Sep 17;43:67-81. doi: 10.1016/j.bioactmat.2024.08.047. eCollection 2025 Jan. Bioact Mater. 2024. PMID: 39328776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials